Typhus vaccine: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 12:19, 3 September 2011 editCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Misplaced Pages← Previous edit		Latest revision as of 19:39, 3 February 2023 edit undoOzzie10aaaa (talk \| contribs)Autopatrolled, Extended confirmed users, New page reviewers213,663 editsm Cleaned up using AutoEd
(30 intermediate revisions by 25 users not shown)
Line 1:		Line 1:
	{{Distinguish\|typhoid vaccine}}		{{Short description\|Inventor - Rudolf Weigl}}{{Distinguish\|typhoid vaccine}}
	{{Drugbox		{{Drugbox
			\| Verifiedfields = changed
	\| verifiedrevid = 365989659		\| verifiedrevid = 365989659
	\| image =		\| image = Weigl vaccine.jpg
			\| caption = Typhus vaccine developed by ]

	<!--Vacine data-->		<!-- Vacine data -->
	\| type = vaccine		\| type = vaccine
	\| target = ]		\| target = ]
	\| vaccine_type = inactivated		\| vaccine_type = inactivated
		⚫	<!-- Clinical data -->

		⚫	\| tradename =
⚫	<!--Clinical data-->
⚫	\| tradename =
	\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->		\| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
	\| pregnancy_US = <!-- A / B / C / D / X -->		\| pregnancy_US = <!-- A / B / C / D / X -->
	\| pregnancy_category =		\| pregnancy_category =
	\| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->		\| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
	\| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->		\| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
	\| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->		\| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
	\| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->		\| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
	\| legal_status =		\| legal_status =
	\| routes_of_administration =		\| routes_of_administration =
		⚫	<!-- Identifiers -->

			\| ChemSpiderID_Ref = {{chemspidercite\|changed\|chemspider}}
⚫	<!--Identifiers-->
	\| ~~CAS_number~~ =		\| ChemSpiderID = none
			\| CAS_number_Ref = {{cascite\|correct\|??}}
			\| CAS_number =
	\| ATC_prefix = J07		\| ATC_prefix = J07
	\| ATC_suffix = AR01		\| ATC_suffix = AR01
	\| PubChem =		\| PubChem =
	\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}		\| DrugBank_Ref = {{drugbankcite\|correct\|drugbank}}
	\| DrugBank =		\| DrugBank =
		⚫	<!-- Chemical data -->

⚫	<!--Chemical data-->
	}}		}}

	'''Typhus vaccine''' is a ] used against ].<ref name="pmid17375000">{{cite journal \|author=Chattopadhyay S, Richards AL \|title=Scrub typhus vaccines: past history and recent developments \|journal=Hum Vaccin \|volume=3 \|issue=3 \|pages=73–80 \|year=2007 \|pmid=17375000 \|doi= \|url=http://www.landesbioscience.com/journals/hv/abstract.php?id=4009}}</ref><ref name="pmid16481526">{{cite journal \|author=Xu G, Chattopadhyay S, Jiang J, ''et al.'' \|title=Short- and long-term immune responses of CD-1 outbred mice to the scrub typhus DNA vaccine candidate: p47Kp \|journal=Ann. N. Y. Acad. Sci. \|volume=1063 \|issue= \|pages=266–9 \|year=2005 \|month=December \|pmid=16481526 \|doi=10.1196/annals.1355.043 \|url=http://www3.interscience.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0077-8923&date=2005&volume=1063&spage=266}}</ref>
			'''Typhus vaccines''' are ]s developed to protect against ].<ref name="pmid17375000">{{cite journal \|vauthors=Chattopadhyay S, Richards AL \|title=Scrub typhus vaccines: past history and recent developments \|journal=Hum Vaccin \|volume=3 \|issue=3 \|pages=73–80 \|year=2007 \|pmid=17375000 \|doi= 10.4161/hv.3.3.4009\|url=http://www.landesbioscience.com/journals/hv/abstract.php?id=4009\|doi-access=free }}</ref> As of 2020 they are not commercially available.<ref name=CDC2017Epi>{{cite web\|title=Epidemic Typhus\|url=https://www.cdc.gov/typhus/epidemic/index.html\|website=www.cdc.gov\|access-date=26 March 2017\|language=en-us\|date=7 March 2017}}</ref><ref name=CDC2017Mu>{{cite web\|title=Murine Typhus\|url=https://www.cdc.gov/typhus/murine/index.html\|website=www.cdc.gov\|access-date=26 March 2017\|language=en-us}}</ref><ref name=CDC2017Scu>{{cite web\|title=Scrub Typhus\|url=https://www.cdc.gov/typhus/scrub/index.html\|website=www.cdc.gov\|access-date=26 March 2017\|language=en-us\|date=7 March 2017}}</ref>

			One typhus vaccine consisted of formaldehyde-inactivated '']''. Two doses were injected subcutaneously four weeks apart. Booster doses were required every six to twelve months.{{cn\|date=September 2022}}

			==See also==
			* ]
			* ]
			* ]

	==References==		==References==
Line 39:		Line 48:

	]		]
			]


			{{vaccine-stub}}

Latest revision as of 19:39, 3 February 2023

Inventor - Rudolf WeiglNot to be confused with typhoid vaccine. Pharmaceutical compound

Typhus vaccine
Vaccine description
Typhus vaccine developed by Rudolf Weigl
Target	Typhus
Vaccine type	Inactivated
Clinical data
ATC code	J07AR01 (WHO)
Identifiers
ChemSpider	none
(what is this?) (verify)

Typhus vaccines are vaccines developed to protect against typhus. As of 2020 they are not commercially available.

One typhus vaccine consisted of formaldehyde-inactivated Rickettsia prowazekii. Two doses were injected subcutaneously four weeks apart. Booster doses were required every six to twelve months.

References

Chattopadhyay S, Richards AL (2007). "Scrub typhus vaccines: past history and recent developments". Hum Vaccin. 3 (3): 73–80. doi:10.4161/hv.3.3.4009. PMID 17375000.
"Epidemic Typhus". www.cdc.gov. 7 March 2017. Retrieved 26 March 2017.
"Murine Typhus". www.cdc.gov. Retrieved 26 March 2017.
"Scrub Typhus". www.cdc.gov. 7 March 2017. Retrieved 26 March 2017.

Artificial induction of immunity / Immunization: Vaccines, Vaccination, Infection, Inoculation (J07)

Development

Classes

Conjugate
Inactivated
Live
- Attenuated
- Heterologous
Subunit/component / Peptide / Virus-like particle / Synthetic
DNA / mRNA
Therapeutic
Toxoid

Administration

Global:
- GAVI Alliance
- NITAG
- SAGE
- Vaccine wastage
- Policy
- Schedule
- Vaccine injury
US:

Vaccines

Bacterial	Anthrax Brucellosis Cholera Diphtheria Hib Leptospirosis Lyme disease Meningococcus MeNZB NmVac4-A/C/Y/W-135 Pertussis Plague Pneumococcal PCV PPSV Q fever Tetanus Tuberculosis BCG Typhoid Ty21a ViCPS Typhus combination: DPT/DTwP/DTaP Td/Tdap research: Clostridioides difficile Group B streptococcal disease Shigellosis
Viral	Adenovirus Chikungunya Ebola rVSV-ZEBOV Flu H1N1 (Pandemrix) H5N1 H5N8 LAIV Hantavirus Hepatitis A Hepatitis B Hepatitis E HPV Cervarix Gardasil Japanese encephalitis Measles Mpox Mumps Polio Sabin Salk Rabies Rotavirus Rubella SARS-CoV-2 Corbevax Bharat Biotech CanSino CoronaVac EpiVacCorona Janssen Kostaive Moderna Novavax Oxford–AstraZeneca Pfizer–BioNTech Sanofi–GSK Sinopharm BIBP Skycovione Sputnik V Valneva Respiratory syncytial virus (RSV) Smallpox Tick-borne encephalitis Varicella zoster Chicken pox Shingles Yellow fever combination: Hepatitis A and B MMR MMRV research: Cytomegalovirus Dengue Epstein–Barr virus Hepatitis C Herpes simplex HIV Zika
Protozoan	Malaria RTS,S research: Trypanosomiasis
Helminthiasis	research: Hookworm Schistosomiasis
Other	Androvax (androstenedione albumin) Cancer vaccines ALVAC-CEA BCG Hepatitis B HPV Cervarix Gardasil Prostvac NicVAX Ovandrotone albumin (Fecundin) TA-CD TA-NIC combination: DTaP-IPV/Hib DTaP-IPV-HepB DTwP-HepB-Hib Hexavalent vaccine

Inventors/
researchers

Controversy

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This article about vaccines or vaccination is a stub. You can help Misplaced Pages by expanding it.

Categories:

Latest revision as of 19:39, 3 February 2023

See also

References